Oral cannabinoid receptor modulator formulations

Patent metadata

Field	Value
Publication number	US-10526318-B2
Application number	US-201815862721-A
Country	US
Kind code	B2
Filing date	Jan 5, 2018
Priority date	Jan 5, 2018
Publication date	Jan 7, 2020
Grant date	Jan 7, 2020

Abstract

Oral formulations of benzofuran compounds which modulate cannabinoid receptors are presented. Methods of using these formulations for treatment of cannabinoid receptor-mediated disease, including neuropathic pain and addition, are also described.

First claim

What is claimed is:

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier suitable for oral administration and the compound

wherein the pharmaceutically acceptable carrier is a hydroxypropyl methylcellulose acetate succinate subtype M (HPMCAS-M) spray-dried dispersion, and wherein the compound is 25% (wt) of the pharmaceutical composition.

2. A method of treating neuropathic pain in a subject, said method comprising administering to the subject in need of such treatment, a therapeutically-effective amount of the pharmaceutical composition according to claim 1 .

Assignees

• Cleveland Clinic Found

Inventors

• Foss Joseph
• Attala Mohamed Naguib

Classifications

• A61K31/443

  containing a five-membered ring with oxygen as a ring hetero atom · CPC title

• A61K9/1652

  Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623) · CPC title

• A61K31/343

  condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone · CPC title

• A61P25/02

  for peripheral neuropathies · CPC title

• A61P25/04

  Centrally acting analgesics, e.g. opioids · CPC title